Sign up to save your podcasts
Or
Share Leslie Kean, MD, PhD - Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Leslie Kean, MD, PhD - Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols
Go online to PeerView.com/KPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell co-stimulation blocking agent abatacept, as well as additional novel strategies being tested in a range of acute and chronic GVHD settings. In this activity from the 2022 Tandem meetings, our expert panelists distill the current evidence on novel therapeutics in the prevention and treatment of GVHD; throughout, they illustrate how and when to integrate novel therapeutics into care, provide guidance on how to prepare for emerging strategies, and offer practical takeaways on the changing nature of GVHD management. Upon completion of this activity, participants should be better able to: Discuss current evidence supporting the use of novel therapeutics as prophylactic or treatment options for acute or chronic graft-versus-host disease (GVHD) in the post-transplant setting, including JAK and BTK inhibitors, T-cell blocking agents, α1-antitrypsin, and ROCK inhibitors, among others, Develop management plans informed by evidence and practice guidelines that incorporate novel therapeutics into the management of acute GVHD, Integrate novel and emerging therapies into management plans for the management of chronic GVHD, including novel combinatorial strategies and/or options for second-line management.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
Go online to PeerView.com/KPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell co-stimulation blocking agent abatacept, as well as additional novel strategies being tested in a range of acute and chronic GVHD settings. In this activity from the 2022 Tandem meetings, our expert panelists distill the current evidence on novel therapeutics in the prevention and treatment of GVHD; throughout, they illustrate how and when to integrate novel therapeutics into care, provide guidance on how to prepare for emerging strategies, and offer practical takeaways on the changing nature of GVHD management. Upon completion of this activity, participants should be better able to: Discuss current evidence supporting the use of novel therapeutics as prophylactic or treatment options for acute or chronic graft-versus-host disease (GVHD) in the post-transplant setting, including JAK and BTK inhibitors, T-cell blocking agents, α1-antitrypsin, and ROCK inhibitors, among others, Develop management plans informed by evidence and practice guidelines that incorporate novel therapeutics into the management of acute GVHD, Integrate novel and emerging therapies into management plans for the management of chronic GVHD, including novel combinatorial strategies and/or options for second-line management.
More shows like PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
View all
JAMA Editors' Summary
129 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
6 Listeners
Lung Cancer Update
31 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
5 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
NEJM This Week
318 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
Research To Practice | Oncology Videos
114 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
JAMA Clinical Reviews
485 Listeners
ASCO Daily News
55 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
Oncology Today with Dr Neil Love
54 Listeners
CCO Oncology Podcast
9 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
38 Listeners